Electrophysiology

Autonomix Medical, Inc. Provides Business Overview and Highlights Upcoming Milestones

Retrieved on: 
Thursday, January 4, 2024
Quality of life, Pain, Disease, Clinical trial, IP, Nervous system, Electrophysiology, Ethanol, Patient, Collateral damage, Medical imaging

THE WOODLANDS, TX, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided a business overview and highlighted upcoming milestones.

Key Points: 
  • THE WOODLANDS, TX, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today provided a business overview and highlighted upcoming milestones.
  • Lori Bisson, Chief Executive Officer of Autonomix, commented, “Autonomix is dedicated to dramatically improving the quality of millions of lives by empowering the nerve-directed treatments of tomorrow.
  • Achieving “proof-of-concept” in this area could open the door to blockbuster diseases, expanding the horizons for the Company’s technology.
  • The smaller and shorter clinical trials potentially translate to more efficient resource utilization, minimizing overall development costs.

AtriCure Appoints Shlomi Nachman to the Board of Directors

Retrieved on: 
Thursday, January 4, 2024
Surgery, Medical Devices, Hospitals, Health, Cardiology, Johnson & Johnson, Electrophysiology, Research, Chemistry, LAA, Medical device, Ear, Face, Growth, Optometry, Patient, Safety, Pharmaceutical industry

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors.

Key Points: 
  • AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced it appointed Shlomi Nachman to its Board of Directors.
  • Prior to that, Mr. Nachman served in various roles with increased scope and responsibilities, including Worldwide President of Biosense Webster and Cordis.
  • “I am thrilled to be joining the AtriCure Board during this exciting time of accelerating growth and profitability,” said Mr. Nachman.
  • I have done extensive diligence on the company’s business, prospects, and end user markets, and believe them to be significantly underpenetrated.

Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter

Retrieved on: 
Wednesday, December 20, 2023
Medical Devices, Hospitals, Clinical Trials, Cardiology, Biotechnology, Radiology, Health, Pharmaceutical, General Health, Patient, PFA, Physician, Research, FDA, Mount Sinai Hospital, 3D, Catheter, Electrophysiology, Femoral vein, Safety, Atrial fibrillation, Medical device

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.

Key Points: 
  • Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter.
  • The catheter is designed to deliver a fast, transmural and fully circumferential ablation in a single energy delivery.
  • The CellFX nsPFA cardiac catheter is integrated with 3D mapping and navigation to deliver a comprehensive visualization and precise ablation delivery solution.
  • The observations to date have been positive but the broad set of risks associated with cardiac surgery remain.

Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm

Retrieved on: 
Tuesday, December 19, 2023
Health care, PFA, Physician, FDA, Boston Scientific, Clarivate, Growth, IDE, COVID-19, Medtronic, Electrophysiology, CLVT, Patient, Organization, Intelligence, EP, Atrial fibrillation, Medtech, Tourism

LONDON, Dec. 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of a new special report series,  Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific. Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm.

Key Points: 
  • The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific.
  • Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm.
  • PFA has emerged as a breakthrough technology for the treatment of atrial fibrillation, attracting significant investment from several companies dedicated to its development.
  • Growth in market revenues will be driven by increasing ablation procedure volumes and the uptake of premium-priced devices.

Clarivate Reveals Stronger Outlook for Pulsed-field Ablation Market and Potential for Device to Revolutionize Treatment Paradigm

Retrieved on: 
Tuesday, December 19, 2023
Health care, PFA, Physician, FDA, Boston Scientific, Clarivate, Growth, IDE, COVID-19, Medtronic, Electrophysiology, CLVT, Patient, Organization, Intelligence, EP, Atrial fibrillation, Medtech, Tourism

LONDON, Dec. 19, 2023 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the launch of a new special report series,  Electrophysiology Mapping and Ablation Devices Market Insights. The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific. Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm.

Key Points: 
  • The Clarivate MedTech Insights reports reveal new forecast predictions for the ablation catheter market in four geographies: the US, Europe, Japan and Asia Pacific.
  • Findings show pulsed-field ablation (PFA) is poised to revolutionize the treatment paradigm.
  • PFA has emerged as a breakthrough technology for the treatment of atrial fibrillation, attracting significant investment from several companies dedicated to its development.
  • Growth in market revenues will be driven by increasing ablation procedure volumes and the uptake of premium-priced devices.

Rapid Growth at Attune Medical Spurs Strategic Hires and Expansion

Retrieved on: 
Thursday, December 14, 2023
Science, Cardiology, Biotechnology, Research, Surgery, General Health, Health, Medical Devices, Associate, Safety, De novo, Quality, Regulatory affairs, Esophagus, University, Digital, MBE, Clinical trial, Clinical research, Fluoroscopy, Multimedia, Patient, Medicine, FDA, Electrophysiology, Marketing, Atrial fibrillation, FHRS, Elekta, NIH, MPH, RAC, Growth, Hospital, Teva Pharmaceuticals, Temperature, CBA, Video game, Medical device, Pharmaceutical industry, MD

Attune Medical, a pioneer in utilizing the esophageal space to proactively manage patient temperature and to reduce the likelihood of esophageal injury during cardiac ablation procedures, announces significant growth with three key additions and expansion of commercial operations.

Key Points: 
  • Attune Medical, a pioneer in utilizing the esophageal space to proactively manage patient temperature and to reduce the likelihood of esophageal injury during cardiac ablation procedures, announces significant growth with three key additions and expansion of commercial operations.
  • (Graphic: Business Wire)
    Melinda Smith, MS, RAC, CBA, joins Attune Medical as VP of Regulatory Affairs leading our global regulatory strategy.
  • In her role with Attune Medical, she will expand efforts in clinical research and study start-up while managing high-profile NIH funded clinical trial efforts.
  • In addition, the company is actively expanding its commercial and clinical teams to accommodate the rapid growth it is experiencing.

Johnson & Johnson MedTech Acquires Laminar, Inc.

Retrieved on: 
Thursday, November 30, 2023
Health, Surgery, Cardiology, Medical Devices, Acquisition, Research, Johnson & Johnson, LAA, Risk, Patient, Arrhythmia, Thrombosis, EPS, Heart, FDA, Electrophysiology, Atrial fibrillation, Stroke, Pharmaceutical industry, Laminar, Ventricular fibrillation

Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).

Key Points: 
  • Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib).
  • Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to customary adjustments, with additional potential clinical and regulatory milestone payments in 2024 and beyond.
  • Laminar joins Johnson & Johnson MedTech as part of Biosense Webster, Inc. – a global leader in cardiac arrhythmia treatment.
  • “We are looking forward to advancing this vision as part of Johnson & Johnson MedTech.”
    “We are excited to welcome Laminar to Johnson & Johnson MedTech,” said Jasmina Brooks, President, Biosense Webster.

AtriCure Releases 2023 ESG Report

Retrieved on: 
Tuesday, November 14, 2023
Other Science, Medical Supplies, FDA, Research, DEI (Diversity, Equity and Inclusion), Other Health, Surgery, Consumer, Environmental, Social and Governance (ESG), Medical Devices, Hospitals, Genetics, Clinical Trials, Professional Services, Cardiology, Biotechnology, Alternative Medicine, Health, Science, Other Consumer, Disclosure, Woman, Social, Emotional intelligence, Corporation, LAA, Sustainability accounting, USB On-The-Go, Student, Patient, Sustainability Accounting Standards Board, ISR, Equity, National Association, Heart, Electrophysiology, Atrial fibrillation, NACD, Public company, Supply, Education, Diversity, Elective surgery, Market capitalization, Inappropriate sinus tachycardia, ESG, Pharmaceutical industry, Nursing

“At AtriCure, our focus on making a positive difference for patients is at the heart of our ESG strategy,” said Michael Carrel, President and Chief Executive Officer at AtriCure.

Key Points: 
  • “At AtriCure, our focus on making a positive difference for patients is at the heart of our ESG strategy,” said Michael Carrel, President and Chief Executive Officer at AtriCure.
  • We are committed to further advancing our ESG programs and improving transparency on our focus areas in the years ahead.”
    Key accomplishments detailed in AtriCure’s 2023 ESG Report include:
    Receiving recognition for Diversity, Equity & Inclusion from the National Association of Corporate Directors (NACD).
  • AtriCure’s 2023 ESG Report aims to address the company’s diverse stakeholders who are interested in ESG-related information, including investors, customers, employees, communities, suppliers, and patients.
  • Please visit the “Corporate Responsibility” section under “About AtriCure” of the company’s website at www.atricure.com/esg to view the report.

HeartBeam Reports Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, November 14, 2023
Data Management, Health, Medical Devices, Technology, Health Technology, Software, Cardiology, Sale, Webcast, Senior, Regulatory affairs, CFO, Boston Scientific, Common stock, Research, Algorithm, FDA, Electrophysiology, SAB, Coronary occlusion, Trial of the century, Splenic infarction, Arrhythmia, Doctor of Philosophy, Patent, United States patent law, AI, Coronavirus Scientific Advisory Board, Physician, Innovation, Medical device, Pharmaceutical industry, Cryptocurrency, Video game, MD

“During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.

Key Points: 
  • “During the third quarter of 2023 we significantly enhanced the HeartBeam team, continued to make steady progress toward upcoming clinical and regulatory milestones, and validated the potential of our VECG technology platform,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam.
  • Research and development expenses for the third quarter of 2023 were $1.6 million, compared to $1.6 million for the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $2.1 million compared to $2.0 million for the third quarter of 2022.
  • Net loss for the third quarter of 2023 was $3.5 million, compared to a net loss of $3.6 million for the third quarter of 2022.

CathVision Unveils ECGenius 3.1 To Improve Workflows and Optimize EGM AI Analyses

Retrieved on: 
Tuesday, December 12, 2023
NYU Langone Health, ECG, Acquisition, Q3, Signal, PVI, Algorithm, Workflow, Intelligence, Software, Diagnosis, AI, Physician, Noise, EP, Medical imaging, Electrophysiology

COPENHAGEN, Denmark, Dec. 12, 2023 /PRNewswire/ -- CathVision, a medical technology company developing innovative electrophysiology solutions designed to enhance clinical decision making in the EP lab, today announced the launch of ECGenius 3.1, an advanced version of the ECGenius™ System software. The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1

Key Points: 
  • The new version improves workflow and streamlines processes to accelerate adoption as electrophysiologists integrate AI analyses into the EP lab, increasing the demand for high-quality signal data.1
    Intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.
  • ECGenius 3.1 delivers several new and enhanced features to provide an improved user experience throughout, including:
    The release of ECGenius 3.1 follows the Q3 launch of the PVI Analyzer™ and Signal Complexity™ algorithms.
  • ECGenius 3.1 makes the workflow transition seamless and strengthens our leadership position in equipping electrophysiologists with the technology necessary to elevate patient outcomes."
  • With exceptional data from the ECGenius System, intelligent automated analyses can effectively enable physicians to confirm the success of ablation efforts.